Combining Forces: Joining Urologists and Medical/Radiation Oncologists to Optimize Treatment for Advanced Prostate Cancer

[摘要] The long-overdue addition of chemotherapy to the list of treatments available for prostate cancer has provided an entirely new perspective on the overall management of this prevalent disease. A consistent rate of therapeutic benefit has been reported with docetaxel alone or in combination with other cytotoxic agents in Phase II trials. Phase III trials of these regimens are currently in progress and may demonstrate a survival advantage over symptomatic treatment with mitoxantrone plus prednisone, in patients with hormone-refractory disease. Many of these data are illustrated herein and they make a strong case for prostate cancer’s chemosensitivity. In addition to the patient benefit provided by the introduction of a new treatment modality, new opportunities for research have emerged. The findings from these trials provide the rationale for the exploration of new, docetaxel-based combinations and other therapeutic options.

[学科分类] 基础医学